<DOC>
	<DOCNO>NCT00696800</DOCNO>
	<brief_summary>To investigate efficacy safety single injection 150 Î¼g Corifollitropin Alfa ( Organon 36286 ) induce multifollicular development control ovarian stimulation use daily recombinant FSH ( recFSH ) reference . The primary hypothesis single injection Corifollitropin Alfa non-inferior daily treatment recFSH initiate multifollicular growth .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety Single Injection Corifollitropin Alfa ( Organon 36286 ) Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone ( FSH ) Reference ( P05787 )</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled , non-inferiority clinical trial investigate efficacy safety new treatment regimen Corifollitropin Alfa , recombinant gonadotropin apply initiate sustain follicular stimulation control ovarian stimulation Assisted Reproductive Technology ( ART ) . For regimen , participant receive single injection Corifollitropin Alfa one week later , treatment continue daily recFSH day trigger final oocyte maturation . In reference group participant receive daily injection recFSH day trigger final oocyte maturation . Non-inferiority ongoing pregnancy rate ( assess least 10 week embryo transfer ) primary endpoint trial . The number oocytes retrieved analyzed co-primary endpoint .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Females couple indication Controlled Ovarian Stimulation ( COS ) invitro fertilization ( IVF ) intracytoplasmic sperm injection ( ICSI ) ; &gt; =18 &lt; =36 year age time sign informed consent ; Body weight &gt; 60 &lt; =90 kg body mass index ( BMI ) &gt; =18 &lt; =32 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Availability ejaculatory sperm ( use donate and/or cryopreserved sperm allow ) ; Willing able sign inform consent . History of/or current ( treat ) endocrine abnormality ; History ovarian hyperresponse ovarian hyperstimulation syndrome ( OHSS ) ; History of/or current polycystic ovary syndrome ( PCOS ) ; More 20 basal antral follicle &lt; 11 mm ( ovary combine ) measure ultrasound scan ( USS ) early follicular phase ( menstrual cycle day 25 ) ; Less 2 ovary ovarian abnormality ( include endometrioma &gt; 10 mm ; visible USS ) ; Presence unilateral bilateral hydrosalphinx ( visible USS ) ; Presence clinically relevant pathology affect uterine cavity fibroid &gt; =5 cm ; More three unsuccessful IVF cycle since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/ human menopausal gonadotropin ( hMG ) treatment ; History recurrent miscarriage ( 3 , even unexplained ) ; FSH &gt; 12 IU/L LH &gt; 12 IU/L measure local laboratory ( sample take early follicular phase : menstrual cycle day 25 ) ; Any clinically relevant abnormal laboratory value base sample take screening phase ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) ; Recent history of/or current epilepsy , human immunodeficiency virus ( HIV ) infection , diabetes , cardiovascular , gastrointestinal , hepatic , renal pulmonary disease ; Abnormal karyotyping patient partner ( karyotyping perform ) ; Smoking 5 cigarette per day ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Previous use Org 36286 ; Use hormonal preparation within 1 month prior randomization ; Hypersensitivity concomitant medication prescribe part treatment regimen protocol ; Administration investigational drug within three month prior sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone substitute hormone antagonist</keyword>
	<keyword>Pharmacological action</keyword>
	<keyword>Randomized</keyword>
	<keyword>Multi-center</keyword>
	<keyword>Multi-national</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Active-controlled</keyword>
	<keyword>Non-inferiority</keyword>
</DOC>